USF Research News

USF’s Tampa Bay Technology Incubator Welcomes SGN NanoPharma

September 27, 2017

New Incubator tenant developing next generation NanoCannabinoid formulations

SGN Nanopharma (left to right): USF students Tobiloba Atinmo and Rawan Rawas, Dr. Praful Pate, Chief Operating Officer of SGN Nanopharma. USF student Sharad Ambardar, Dr. Navdeep Jaikaria, Chief Executive Officer, and Dr. Pranav Patel, Director of Research and Development.

TAMPA, Fla. – SGN NanoPharma, a clinical-stage developer of nanotherapeutics, has joined USF’s Tampa Bay Technology Incubator (TBTI). The company is focused using proprietary nanotechnologies to generate better and more cost-effective pharmaceuticals.

SGN NanoPharma is developing and commercializing enhanced pharmaceuticals through reformulating and improvising FDA approved drugs whose safety, side effects and efficacy are not ideal and can be improved to provide better patient benefit. SGN NanoPharma is using its proprietary Micellar Nano Particulate (MNP) technology platform to achieve this goal. The MNP Technology platform improves the solubility and bioavailability of difficult to formulate drugs, which in-turn leads to lowering of dosage required and/or an improvement in efficacy and safety of these drugs.

The company is now focusing on developing NanoCannabinoids to safely deliver large dose therapies as an alternative to many traditional medicines currently considered over-prescribed and potentially life-threatening.

“Our mission is to develop next generation nano-cannabinoid formulations for the global treatment of various inflammatory diseases, ophthalmic indications, epilepsy and other neural disorders,” said Navdeep Jaikaria, Ph.D. CEO and Chairman of SGN NanoPharma. “Marriage of nanotechnology with cannabinoids and new therapeutics present us with an opportunity to make a significant global impact in medicine.”

As part of the TBTI incubator program, SGN NanoPharma will have access to state-of-the-art wet lab facilities, scientific equipment, funding opportunities and Incubator programming.

"Joining the TBTI provides companies like SGN NanoPharma with a myriad of resources for successful business development and technology commercialization,” said Valerie Landrio McDevitt, associate vice president for technology transfer and business partnerships.

“Having the support of the TBTI program is invaluable,” Jaikaria said. “The opportunities for matching grant funding and the USF talent pool of researchers and students will help us achieve our goal of commercializing products locally in Florida. We are quite pleased that we have already procured funding for two grants under the matching grants initiative at USF and we look forward to collaborating with the USF faculty on these.”

For more information about SGN NanoPharma, please visit

About SGN NanoPharma
SGN NanoPharma is an innovative, clinical-stage and revenue-generating developer of nanotherapeutics. The Company combines proprietary nanotechnologies with structural biology to generate superior solutions by (a) reformulating FDA approved drugs that are sub-optimal and (b) by developing novel therapies.

The Company is committed to the development of nano-cannabinoid candidate products targeting transdermal delivery, increased bioavailability, and reduced psychotropic effects. Our aim is to safely deliver large dose therapies as an alternative to many traditional medicines such as opiates, which are currently considered over prescribed and potentially life-threatening.

The company currently has a drug approved and launched in India and several others waiting approval for India and Emerging markets. The company is also developing its own manufacturing capabilities.

About the Tampa Bay Technology Incubator
The University of South Florida's Tampa Bay Technology Incubator (TBTI) is one vehicle through which USF CONNECT grows successful companies. TBTI supports technology research as a catalyst for economic development and advocates the creation and development of facilities for high-technology companies and related support functions. USF CONNECT focuses on the needs of Tampa Bay's technology and bio/life sciences entrepreneurs throughout the business life cycle, providing the facilities, partners, and resources for successful business development. USF CONNECT offers access to technologies, workforce programs, technology commercialization, critical research equipment, and incubator facilities, adding value and delivering targeted, high level expertise to its member businesses.

About the University of South Florida
The University of South Florida, established in 1956 and located in Tampa, is a high-impact, global research university dedicated to student success. The USF System includes three, separately accredited institutions: USF; USF St. Petersburg; and USF Sarasota-Manatee. Serving more than 49,000 students, the USF System has an annual budget of $1.6 billion and an annual economic impact of $4.4 billion. USF is ranked in the Top 30 nationally for research expenditures among public universities, according to the National Science Foundation. In 2016, the Florida Legislature designated USF as “Emerging Preeminent”, placing USF in an elite category among the state’s 12 public universities. USF is a member of the American Athletic Conference.